This company has been marked as potentially delisted and may not be actively trading. NASDAQ:PRNB Principia Biopharma (PRNB) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Principia Biopharma Stock (NASDAQ:PRNB) 30 days 90 days 365 days Advanced Chart Get Principia Biopharma alerts:Sign Up Key Stats Today's Range$100.05▼$100.0550-Day Range$99.95▼$100.2752-Week Range$25.35▼$101.89VolumeN/AAverage Volume729,676 shsMarket Capitalization$3.32 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Principia Biopharma Inc., a late-stage biopharmaceutical company, focuses on developing novel therapies for immunology and oncology. The company is developing PRN1008, an inhibitor that is in Phase III clinical trial for the treatment of pemphigus, a chronic skin disease, as well as in Phase II clinical trial to treat immune thrombocytopenic purpura. It is also developing PRN2246/SAR442168, an inhibitor, which has completed Phase I clinical trial for treating multiple sclerosis (MS) and other central nervous system (CNS) diseases; PRN1371, a drug candidate that is in Phase I clinical trial for the treatment of solid tumors; and oral small molecule inhibitors of the immunoproteasome. The company has a collaboration agreement with Genzyme Corporation to develop relapsing and progressive MS and other diseases of the CNS. Principia Biopharma Inc. was incorporated in 2008 and is headquartered in South San Francisco, California. Read More Receive PRNB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Principia Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address PRNB Stock News HeadlinesSports Final: Maty Mauk ready to coach Principia High SchoolApril 25, 2025 | msn.comFORE Biotherapeutics Names Michael Byrnes as Chief Financial OfficerAugust 12, 2024 | finance.yahoo.comGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bill Gates has backed four companies in this space. The World Economic Forum calls it “the most exciting human discovery since fire.” Whitney Tilson believes this trend could mint a new class of wealthy investors—and he’s sharing one stock to watch now, for free. | Stansberry Research (Ad)Principia College names new presidentMay 28, 2023 | bizjournals.comCBI appoints ethics consultancy Principia Advisory in fight for survivalMay 5, 2023 | theguardian.comTruist Securities Downgrades 9 Meters Biopharma to Hold, Announces $38 Price TargetMarch 22, 2023 | benzinga.comWooly mammoth tusk discovered on Principia College campusJanuary 17, 2023 | msn.comDodge Construction Network Acquires Principia Consulting, Expanding Dodge Advisory Services’ CapabilitiesOctober 12, 2022 | finance.yahoo.comSee More Headlines PRNB Stock Analysis - Frequently Asked Questions How were Principia Biopharma's earnings last quarter? Principia Biopharma Inc. (NASDAQ:PRNB) posted its earnings results on Thursday, August, 6th. The company reported $0.31 EPS for the quarter, beating the consensus estimate of ($1.03) by $1.34. The firm earned $50 million during the quarter, compared to analyst estimates of $50 million. When did Principia Biopharma IPO? Principia Biopharma (PRNB) raised $75 million in an IPO on Friday, September 14th 2018. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch, Leerink Partners and Wells Fargo Securities acted as the underwriters for the IPO and Baird was co-manager. What other stocks do shareholders of Principia Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Principia Biopharma investors own include Pfizer (PFE), Advanced Micro Devices (AMD), AbbVie (ABBV), Bristol Myers Squibb (BMY), Cisco Systems (CSCO), QUALCOMM (QCOM) and VBI Vaccines (VBIV). Company Calendar Last Earnings8/06/2020Today8/24/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:PRNB CIKN/A Webwww.principiabio.com Phone650-416-7700FaxN/AEmployees65Year FoundedN/AProfitability EPS (Trailing Twelve Months)($2.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$53.79 million Net MarginsN/A Pretax MarginN/A Return on Equity-23.08% Return on Assets-21.11% Debt Debt-to-Equity RatioN/A Current Ratio17.01 Quick Ratio17.01 Sales & Book Value Annual Sales$35.16 million Price / Sales94.50 Cash FlowN/A Price / Cash FlowN/A Book Value$10.95 per share Price / Book9.14Miscellaneous Outstanding Shares33,209,000Free FloatN/AMarket Cap$3.32 billion OptionableNot Optionable Beta0.86 These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:PRNB) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersNations are at war over what’s in this boxA resource known as Element 29 is quickly becoming one of the most sought-after materials on the planet. Goldm...Behind the Markets | SponsoredCould This Be the End of Retirement Worries?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTrump’s “new dollar” could shock Americans"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.On a quiet Friday afternoon, one trader spotted an overlooked stock. He bought shares. He shut down his ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Principia Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Principia Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.